LR-HEALTH-&-BEAUTY
15.10.2019 17:25:30 CEST | Business Wire | Press release
LR Health & Beauty is further expanding its Aloe vera product portfolio with its new product Aloe Vera Drinking Gel Immune Plus. The development and manufacturing of Aloe vera products has been one of the core competences of the global direct sales company for more than 17 years. True to the motto "More quality for your life", LR now presents Immune Plus as a premium product to support the immune system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005834/en/
The Aloe Vera Drinking Gels have been LR’s bestsellers since 2002. They offer support in different life situations and are available in various flavors. The special feature of Immune Plus is the synergetic interaction of the ingredients – 85% Aloe vera leaf gel with 8% honey, 6% ginger juice and lemon juice, enriched with vitamin C, zinc and selenium – which have a holistic strengthening effect on the immune system. “We are convinced that with our high-quality product innovation in the field of nutritional supplements, we are continuing the success story of our Aloe Vera Drinking Gels”, states Andreas Friesch, CEO of LR Health & Beauty.
All Aloe Vera Drinking Gels meet the strict internal quality standards and are also distinguished by the quality seal of the SGS INSTITUT FRESENIUS and the International Aloe Science Council (IASC). Regular inspections by the IASC ensure high Aloe vera quality – from cultivation to processing in Germany. Only high-quality Aloe vera gel is used for the products. LR obtains the gel from Mexico, where the plant is cultivated on nutrient-rich volcanic soil. Another seal of quality: SGS INSTITUT FRESENIUS regularly checks LR’s Aloe Vera Drinking Gels, makes blind purchases, checks the finished products and packaging and once a year inspects the production facilities. “Quality is our top priority. This is why, in addition to our own extensive laboratory tests, we also have our Drinking Gels inspected by renowned, independent institutes,” says Andreas Friesch.
With annual processing of around 12,000 tons of Aloe vera leaves, LR is one of the world’s largest manufacturers of Aloe vera products. In addition to the Aloe Vera Drinking Gel, the company’s Aloe vera expertise is also reflected in the brand LR ALOE VIA, which covers the areas of care, cleaning and regeneration.
LR Health & Beauty
The LR Group, headquartered in Ahlen (Germany), produces and markets various beauty and health products in 28 countries. These include care and decorative cosmetics, dietary supplements and perfumes. The processing of Aloe vera has been one of LR Health & Beauty's core competences for over 17 years. In Ahlen, the company has Europe's most modern Aloe vera production facility for Aloe Vera Drinking Gel. With 1,100 employees and thousands of registered sales partners and customers, LR is one of the leading direct sales companies in Europe.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005834/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom